Search the Newsreel

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)

Analysts have provided new ratings for several healthcare companies. Truist Financial maintained a Buy rating on Genmab (GMAB), while Deutsche Bank maintained a Hold rating on Definitive Healthcare Corp (DH). Additionally, Deutsche Bank downgraded Atai Beckley N.V. (ATAI) to Hold.

Why Generation Mining Ltd stock is rising today

What's Going On With Generation Mining Ltd Stock Thursday?

Generation Mining Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Genmab Files Updated Charter, Extends Share-Issuance Authority Through 2030

Genmab A/S has filed an updated Articles of Association with the SEC, documenting a nominal share capital of DKK 62,377,844 and extending the board's authority to issue shares, warrants, and convertible debt through 2029 and 2030. This follows a recent capital increase from employee …

[6-K] GENMAB A/S Current Report (Foreign Issuer)

Genmab A/S has filed a Form 6-K report with the SEC, furnishing its Articles of Association. This report is incorporated by reference into six of Genmab's existing Form S-8 registration statements, indicating a change to their incorporated content. The filing was accepted by SEC …

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More

This article provides a rundown of top Wall Street analyst research calls for Wednesday, August 12, 2026, featuring upgrades, downgrades, and new initiations for various companies like Hilton Worldwide, The Gap, Intuitive Surgical, Merck, and Novo Nordisk. It also covers pre-market stock futures, bond …

Generation Mining Confirms Early Marathon Project Bids Align With Feasibility Costs

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages

Genmab A/S (NASDAQ:GMAB) has received an average "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $39.50, suggesting upside from its current $30.85 share price. The company recently surpassed quarterly earnings estimates, reporting $0.54 EPS against a $0.37 consensus and …

Genmab (GMAB) boosts share capital via DKK 37.9m employee warrant exercise

Genmab A/S has announced a capital increase of 24,592 shares, resulting from the exercise of employee warrants, which will generate approximately DKK 37.9 million for the company. This increase represents about 0.04% of Genmab's total share capital, which will now stand at DKK 62,377,844. …

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of …

Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)

Goldman Sachs has reaffirmed its Buy rating for Genmab A/S (0MGB) with a price target of $33.50, following a report by Rajan Sharma. UBS also issued a Buy rating for Genmab, though Morgan Stanley maintained a Hold rating on the same day. Genmab's current …

Genmab (CPSE:GMAB) Lifts 2026 Outlook As Pipeline Progress Keeps Undervalued Narrative Alive

Genmab (CPSE:GMAB) has increased its 2026 revenue outlook after strong Q2 results, regulatory advancements in Europe, and positive Phase III data for key pipeline drugs. Despite a recent share price surge, the stock is considered 16.4% undervalued, with a fair value of DKK2,392.08 compared …

Genmab (CPSE:GMAB) Stock Revenue Strength Meets Profit Pressure

Genmab (CPSE:GMAB) reported strong Q2 2026 revenue of US$1.16 billion, up 24.9% year-over-year, but net income and basic EPS declined. The company's proprietary product sales are growing, particularly EPKINLY and Tivdak, supporting the argument that Genmab is diversifying beyond royalty income. However, profit margins …

Genmab A/S (GMAB) Aktuelle Aktien-News

Genmab AS earnings beat by $0.15, revenue topped estimates

Genmab AS (NASDAQ: GMAB) reported strong second-quarter results, with EPS of $0.49, exceeding analyst estimates by $0.15. The company also surpassed revenue expectations, bringing in $1.16 billion against a consensus of $1.1 billion. This positive earnings report contributed to significant stock price growth over …

Guggenheim Boosts Genmab A/S (NASDAQ:GMAB) Price Target to $42.00

Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook

Genmab A/S Stock 12‑Month Price Target Raised to $38.16, Implies 28% Upside

Analysts have increased the average 12-month price target for Genmab A/S (GMAB) stock from $37.7 to $38.16, representing a potential 28% upside from its August 6 closing price. This revised target is based on estimates from 23 analysts, with a consensus "Buy" rating maintained …

Why is Genmab stock surging today?

Genmab stock surged 9.2% today after the biotech company reported a strong second-quarter earnings beat and raised its full-year revenue guidance. The positive performance was driven by increased royalty revenues from DARZALEX and stronger net sales of EPKINLY, alongside statistically significant Phase III clinical …

Genmab A/S (NASDAQ:GMAB) Issues Earnings Results, Beats Expectations By $0.12 EPS

Genmab A/S Q2 2026 Earnings Call Transcript

This article first appeared on GuruFocus. Total Revenue Growth: Increased 25% year-over-year in the first half of 2026. Proprietary Portfolio Sales: Totaled DKK396 million, a 37% increase compared to the same period last year. EPKINLY Sales: Grew to DKK312 million in the first half, …

Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

This article first appeared on GuruFocus. Total Revenue Growth: Increased 25% year-over-year in the first half of 2026. Proprietary Portfolio Sales: Totaled DKK396 million, a 37% increase compared to the same period last year. EPKINLY Sales: Grew to DKK312 million in the first half, …

Genmab H1 2026 slides: 25% revenue growth, raised guidance

Genmab reported strong first-half 2026 results, achieving 25% total revenue growth and raising its full-year financial outlook. The company highlighted significant momentum in its proprietary medicines, particularly EPKINLY, which saw 48% year-over-year sales growth. Despite the positive operational update and increased guidance, shares experienced …

Genmab shares jump 8% after upbeat results prompt 2026 outlook raise

Investing.com -- Genmab shares jumped over 8% on Friday, a day after the Danish biotech beat second-quarter expectations and raised its 2026 sales and profit outlook, while confirming a critical bispecific-antibody drug trial readout due in the fourth quarter would be an early look …

Press Release: Genmab Announces Financial Results for the First Half of 2026

Genmab has announced its financial results for the first half of 2026. The company reported significant revenue growth driven by its diverse portfolio of oncology treatments and collaborations. Genmab highlighted strong progress in clinical development programs and reiterated its financial guidance for the full …

Genmab A/S (GMAB) Releases Q2 2026 Earnings: Revenue Up 24.9%, Net Income Falls 9.8%

Genmab A/S (GMAB) reported a 24.9% increase in Q2 2026 revenue, reaching $1.2 billion, while gross profit rose to $1.1 billion. However, net income attributable to common shareholders fell by 9.8% to $303 million, and diluted EPS was $0.49. The company also saw significant …

Genmab Announces Financial Results for the First Half of 2026

Genmab A/S August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival …

Genmab A/S (GMAB) Earnings Date and Reports 2026

Genmab A/S (GMAB) raises 2026 outlook on DARZALEX and EPKINLY growth

Why Generation Mining Ltd stock is skyrocketing today

Genmab A/S (GMAB) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Earnings To Watch: Genmab AS (GMAB) Q2 2026 -- GF Value Sees 47% Upside